Atopic Dermatitis

Individuals with atopic dermatitis carried an elevated risk for asthma compared with those who did not have AD, according to a study.

Lebrikizumab had “generally consistent” results in improving atopic dermatitis across different races, according to results of a phase 2b study presented at Maui Derm for Dermatologists.

Patients with moderate to severe atopic dermatitis experienced improvement in symptoms when treated with tralokinumab plus topical corticosteroids, according to a study presented at the Winter Clinical Dermatology Conference.

Arcutis Biotherapeutics has begun two phase 3 trials of topical roflumilast cream for the treatment of atopic dermatitis.

The marketing authorization for Dupixent has been extended in the European Union to include children ages 6 to 11 years with severe atopic dermatitis, Regeneron and Sanofi announced in a press release.

Patients with moderate to severe atopic dermatitis had a greater improvement with abrocitinib 100 mg or 200 mg than with placebo, according to pooled results presented at the European Academy of Dermatology and Venereology virtual congress.

Researchers discussed racial and ethnic disparities in various aspects of allergy at this year’s virtual meeting of the American College of Allergy, Asthma and Immunology.

Patients with skin allergies who wear certain types of face masks may experience adverse events, according to a presenter at this year’s virtual American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

Routine laboratory monitoring is not required for children with severe atopic dermatitis during treatment with dupilumab, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.

Two phase 3 clinical trials of upadacitinib showed positive results in adolescent and adult patients with atopic dermatitis, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.